Gilead SciencesGILD

NASDAQ · USA · Segment 3 of 8 in the Medicine, pharma & life science value chain: Biotech & innovation

HIV treatment is the heart of it, Biktarvy above all, with cell therapy in oncology growing alongside.

Biotech & innovation: Innovation-driven biotech companies focused on novel treatment modalities.

Key metrics

Market cap

$170B

Price

$146.74

Today

+0.4%

Return YTD

+19.0%

Return 1Y

+25.8%

P/E

—

P/S

5.6

P/B

14.4

Data as of 2026-08-25 · updates daily after U.S. close

Theme exposure

BiotechHIVOncology

In the value chain

Products & services

HIV (Biktarvy)
Oncology (cell therapy)
Liver diseases

Competitors

GSK/ViiV
Merck
Bristol Myers Squibb

Risks

Dependence on HIV franchise
Pipeline execution

Supply chain

Supplies →

McKessonMCK CencoraCOR Cardinal HealthCAH

← Suppliers

IQVIA HoldingsIQV

Full supply chain for GILD →

Same segment: Biotech & innovation

AmgenAMGN Vertex PharmaceuticalsVRTX RegeneronREGN BiogenBIIB Alnylam PharmaceuticalsALNY ModernaMRNA IncyteINCY United TherapeuticsUTHR

Compare GILD

GILD vs AMGN GILD vs VRTX GILD vs REGN GILD vs BIIB GILD vs ALNY GILD vs MRNA

See where Gilead Sciences sits in the full Medicine, pharma & life science map: every segment from upstream suppliers to end markets, with daily metrics.Open the Life science value chain →